510(k) Report

510(k) · Cleared

Cleared

Tacrolimus Assay Kit

K203833510(k) TraditionalCleared Jan 27, 2023758-day reviewClass II21 CFR 862.1678

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Shanghai Genext Medical Technology Co., Ltd. · MLM Enzyme Immunoassay, Tracrolimus

Cleared on Jan 27, 2023 as substantially equivalent to K070820 (Fujirebio Diagnostics,Inc., 2007) after a 758-day review. Its family tree reaches back 2 generations to 1997.

Decided
Jan 27, 2023
Review
758 days
Class
Class II
Product code
MLM
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to P970007 (1997). No later device cites it as a predicate yet.

  1. Root · 2 generations backP970007 Imx Tacrolimus II AssayAbbott Laboratories · 1997 · Recalled
  2. 1 generation backK070820 Architect Tacrolimus: Model 1L77Fujirebio Diagnostics,Inc. · 2007 · Recalled
  3. This deviceK203833 Tacrolimus Assay KitShanghai Genext Medical Technology Co., Ltd. · 2023
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2P970007Imx Tacrolimus II AssayAbbott Laboratories19972
−1K070820Architect Tacrolimus: Model 1L77Fujirebio Diagnostics,Inc.20071
0 (this device)K203833Tacrolimus Assay KitShanghai Genext Medical Technology Co., Ltd.2023—
FIG. 1 — Lineage of K203833, 1997–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MLM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K070820Architect Tacrolimus: Model 1L77
Summary page 5
…e FK506 can be calculated by measuring the absorbance at 546 nm. Substantial Equivalence Information Predicate Device Identification: ARCHITECT TACROLIMUS: MODEL lL 77 (K070820) Comparison with Predicate: Device & Predicate Candidate Device Predicate Device…
Fujirebio Diagnostics,Inc.20071

Also cleared against K070820: 3 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 26 years and passes through 3 companies; a new generation was cleared every 15.5 years on median.
  • 2 of the 2 ancestors have a recall of any class.
  • 3 other devices also cite its predicate K070820.

How does its category compare?

All MLM devices

MLM Enzyme Immunoassay, Tracrolimus: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · MLM

1in 2023

2007: 22013: 12015: 12018: 12023: 1
2007high 2 (2007) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MLM

Too few MLM 510(k)s in any year since 2007 to give a median.

Recalls per year · MLM

1in 2013

2010: 22012: 12013: 12026 (partial year): 1
2007high 2 (2010) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MLM

8in 2025

2007: 42010: 52011: 42012: 312013: 752014: 62015: 12016: 22017: 22018: 262019: 72020: 42021: 12022: 232023: 542024: 622025: 8
2007high 75 (2013) · low 0 (2008)2025

MAUDE reports naming product code MLM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—04
20080—00
20090—00
20100—25
20110—04
20120—131
20131—175
20140—06
20151—01
20160—02
20170—02
20181—026
20190—07
20200—04
20210—01
20220—023
20231—054
20240—062
20250—08
20260—1—

What is it indicated for?

The Tacrolimus Assay Kit is used for quantitative determination of the tacrolimus concentration in human whole blood on the Beckman Coulter AU480. It is to be used as an aid in the management of liver and kidney allograft patients receiving tacrolimus therapy.

For In Vitro Diagnostic Use.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K203833: Tacrolimus Assay Kit.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K203833

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026